Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for severe liver conditions. Its primary product candidate is pemvidutide, an investigational dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company focuses entirely on clinical research and development without commercial operating segments. Because its therapies are still undergoing clinical evaluation, the company has no commercial customers; its treatments are intended for patients suffering from metabolic and alcohol-related liver diseases.

Operationally, the company carries out clinical trials throughout the United States, encompassing fifteen trial sites for its alcohol use disorder study and thirty-four sites for its alcohol-associated liver disease study. Over seven hundred human participants have received its lead drug across eight completed and two ongoing clinical trials. In addition, the business pursues patent protections across several international territories, including the United States, Europe, Japan, and Canada. The provided text does not identify the location of the company's corporate headquarters.

Summary of the business section of Altimmune's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2016, we employed 13 persons, including 6 individuals engaged in research and development activities and 7 individuals engaged in general and administrative functions, such as human resources, finance and accounting.”